In patients with high triacylglycerol levels and low HDL-cholesterol , fenofibrate reduced total cardiovascular outcomes by 30 % ( 95 % CI -7 % , 54 % ) in women and 24 % ( 95 % CI 2 % , 42 % ) in men , with no treatment-by-sex interaction ( p > 0.1 ) .